Skip to main content
Premium Trial:

Request an Annual Quote

ArcticZymes, Tataa Ink Sales, Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian enzymes firm ArcticZymes and Swedish gene expression profiling company Tataa Biocenter today announced a mutual sales and distribution deal covering Europe.

The terms of the agreement calls for Tataa to sell ArcticZymes' heat-labile enzymes for use in contamination control through its sales channels. Tataa will also integrate ArcticZymes' products into its range of courses.

Additionally, ArcticZymes will launch two reference gene panels and the ValidPrime kits series from Tataa. The kits offer for the first time a "rational and economical tool" for determining DNA contamination level, the companies said.

Financial and other terms of the deal were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.